The DUS1L Knockout HEK293T Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HEK293T embryonic kidney epithelial cell line. This product features targeted disruption of the DUS1L gene, eliminating functional DUS1L protein expression. As a polyclonal pool, this population comprises a heterogeneous mixture of edited cells, providing a robust and reproducible loss-of-function model for studying DUS1L-dependent biology without the clonal variability associated with single-cell derived lines.
The parental HEK293T cell line is a widely utilized human embryonic kidney epithelial cell line that stably expresses the SV40 large T antigen, enabling high-level episomal replication of plasmids containing the SV40 origin. This property makes HEK293T cells exceptionally efficient for transient transfection, recombinant protein production, and lentiviral packaging. Their robust growth characteristics and well-characterized biology render them an ideal chassis for generating gene knockouts, particularly for investigations requiring subsequent complementation studies or viral-based delivery of constructs.
DUS1L encodes a tRNA-dihydrouridine synthase that catalyzes the reduction of uridine to dihydrouridine in the D-loop of specific tRNA substrates, a modification critical for tRNA structural stability and translational efficiency. DUS1L function is intimately linked to the tRNA modification machinery, interacting with components of the tRNA modification complex and the ribosome. Its activity is regulated by transcriptional programs and nutrient-sensing pathways, and its loss disrupts the dihydrouridine status of target tRNAs, leading to impaired translation of codon-biased mRNAs and global protein synthesis defects. Consequently, DUS1L influences cellular stress responses and metabolic adaptation through its downstream effects on tRNA stability and ribosome function.
In the HEK293T background, disruption of DUS1L provides a controllable system to dissect the cellular consequences of impaired tRNA dihydrouridine modification. The knockout cells are expected to exhibit reduced dihydrouridine levels in target tRNAs, resulting in decreased translation fidelity and efficiency, particularly for transcripts with high codon demand. This can trigger proteotoxic stress, unfolded protein response activation, and altered cell cycle progression, mimicking aspects of human dihydrouridine deficiency syndromes. Moreover, since HEK293T cells are of kidney epithelial origin and permissive for oncogenic transformation, this model offers a tractable platform to investigate the interplay between tRNA modification status and tumorigenesis.
Researchers can employ this DUS1L knockout polyclonal cell population in a wide array of functional assays, including ribosome footprinting and polysome profiling to assess translational changes, LC-MS-based tRNA modification profiling to directly quantify dihydrouridine levels, and Western blotting or RT-qPCR to monitor stress response markers and translation-related signaling. Cell growth assays under metabolic or proteotoxic stress conditions further reveal the role of DUS1L in cellular fitness. Additionally, these cells serve as a valuable starting point for cancer cell line engineering, enabling rescue experiments with wild-type or mutant DUS1L variants to map structure-function relationships. For further information and detailed protocols, please contact Ascent Research.
